China’s Biopharma Sector Just Hit a Profitability Tipping PointGlobal Report·Jul 21 at 04:13 AM01801-0.96%06160-0.82%
BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 millionPUBT·Jul 17 at 04:31 PM06160-0.82%BGNE0.00%
Hong Kong's Innovation Divide: Blockbuster Drugs, AI Pivots, and Legacy ExitsGlobal Report·Jul 14 at 06:47 AM06160-0.82%02013+5.22%
Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform RatingAASTOCKS News·Jul 13 at 03:20 AMONC-1.57%06160-0.82%
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline ProgressTip Ranks·Jul 12 at 07:25 PM06160-0.82%688235+0.81%
BeOne Medicines Advances Minority-Focused Cancer Trial With Tislelizumab ComboTip Ranks·Jul 9 at 11:32 AM06160-0.82%ONC-1.57%
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)Tip Ranks·Jul 7 at 12:15 AMONC-1.57%BGNE0.00%
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma | ONC Stock NewsStockTitan·Jun 29 at 09:00 PMONC-1.57%BGNE0.00%
Hong Kong's 2026 Biotech Circus: Playing Shareholders and Faking Foreign RootsGlobal Report·Jun 26 at 04:06 AM01801-0.96%06160-0.82%
BeOne Medicines Chief Executive Officer Sold Shares Worth Over $933KTradingView·Jun 25 at 04:20 PM688235+0.81%ONC-1.57%
BeOne Medicines Executives Quietly Cash In on a Wave of Insider Stock SalesTip Ranks·Jun 18 at 09:06 PMONC-1.57%688235+0.81%
BeOne Medicines Chief Executive Officer Sold Shares Worth Over $980KTradingView·Jun 18 at 04:20 PMBGNE0.00%06160-0.82%
BeOne Medicines Grants New Equity Awards Under 2016 Incentive PlanTip Ranks·Jun 18 at 08:46 AMBGNE0.00%06160-0.82%
